Comprehensive Financial Planning Inc. PA Makes New $190,000 Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Comprehensive Financial Planning Inc. PA acquired a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 28,106 shares of the company’s stock, valued at approximately $190,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company lifted its holdings in shares of Recursion Pharmaceuticals by 32.6% in the second quarter. The Manufacturers Life Insurance Company now owns 111,613 shares of the company’s stock valued at $837,000 after purchasing an additional 27,440 shares in the last quarter. SG Americas Securities LLC grew its stake in shares of Recursion Pharmaceuticals by 249.0% during the 3rd quarter. SG Americas Securities LLC now owns 89,325 shares of the company’s stock valued at $589,000 after buying an additional 63,727 shares during the period. Handelsbanken Fonder AB raised its holdings in shares of Recursion Pharmaceuticals by 33.4% in the 3rd quarter. Handelsbanken Fonder AB now owns 69,500 shares of the company’s stock worth $458,000 after purchasing an additional 17,400 shares during the period. Exchange Traded Concepts LLC grew its stake in Recursion Pharmaceuticals by 24.9% during the third quarter. Exchange Traded Concepts LLC now owns 25,182 shares of the company’s stock worth $166,000 after buying an additional 5,021 shares during the period. Finally, Vontobel Holding Ltd. purchased a new stake in Recursion Pharmaceuticals during the 3rd quarter worth $70,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $7.64, for a total transaction of $87,455.08. Following the sale, the director now owns 7,066,113 shares in the company, valued at $53,985,103.32. This represents a 0.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total value of $114,900.00. Following the completion of the transaction, the chief financial officer now owns 1,499,631 shares of the company’s stock, valued at approximately $11,487,173.46. The trade was a 0.99 % decrease in their position. The disclosure for this sale can be found here. Insiders own 15.75% of the company’s stock.

Recursion Pharmaceuticals Price Performance

RXRX stock opened at $7.49 on Monday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The stock’s 50 day moving average is $7.15 and its two-hundred day moving average is $6.89. Recursion Pharmaceuticals, Inc. has a 52-week low of $5.60 and a 52-week high of $15.74.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. KeyCorp reduced their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.